Clincosm LogoSign in Get a demo

Eyecontrol coMmunication Platform for dEliRium manaGemEnt in Intensive Care Units (EMERGE)

Sponsor
Beth Israel Deaconess Medical Center (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06029244
Collaborator
BIRD (Israel-United States Binational Industrial Research and Development) Foundation- Funding agency (Other), Rabin Medical Center (Other), Assuta Medical Center (Other), Eyefree Assisting Communication Ltd (Industry)
160
Enrollment
3
Locations
2
Arms
17
Anticipated Duration (Months)
53.3
Patients Per Site
3.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this research is to investigate whether addition of the EyeControl-Pro platform as an adjunct to standard guideline-based intensive care unit management of critically ill patients is effective in reducing delirium incidence and severity.

Condition or Disease Intervention/Treatment Phase
  • Device: EyeControl-Pro
  • Other: Control
 N/A

Detailed Description

This is a prospective, binational, single-blind, multicenter, randomized control trial, conducted according to international good clinical practice (GCP) ethical and quality standards. Critically ill, mechanically ventilated patients aged >=50 years with Richmond Agitation Sedation Scale (RASS) score of -3 to +1 (at time of screening) who are anticipated to require ventilation for >=24 hours will be eligible for recruitment. The study will be conducted simultaneously at Beth Israel Deaconess Medical Center (BIDMC) Boston, USA, Assuta Ashdod Medical Center (Ashdod, Israel) and Rabin Medical Center (Petah Tikvah, Israel) with BIDMC contributing up to 50% of the total enrollment. Participants will be randomized to either a) sham device or b) active intervention arm (details described below). Legally appointed representatives, patients and caregiver teams will be administered an optional questionnaire to assess their experience with the study device at the conclusion of the study protocol. Study subjects will be administered the telephone-Montreal Cognitive Assessment (t-MoCA); total score of 22 - missing 8 points present in Montreal Cognitive Assessment (MoCA) pertaining to drawing/executive function not feasible over phone) or MoCA (if still in-hospital; assessed out of total score of 30) and Hospital Anxiety and Depression Scale (HADS) questionnaire 30 days post-randomization. Hebrew versions of these questionnaires will be used at Israeli sites.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
160 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Study participants will be randomized to either a) EyeControl-Pro assisted active intervention arm or b) sham controlStudy participants will be randomized to either a) EyeControl-Pro assisted active intervention arm or b) sham control
Masking:
None (Open Label)
Masking Description:
Patients will be unblinded, or unmasked, to treatment allocation given the nature of the intervention.
Primary Purpose:
Treatment
Official Title:
Eyecontrol coMmunication Platform for dEliRium manaGemEnt in Intensive Care Units (EMERGE) : A Multicenter Randomized Controlled Trial
Anticipated Study Start Date :
Oct 1, 2023
Anticipated Primary Completion Date :
Jan 31, 2025
Anticipated Study Completion Date :
Mar 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: EyeControl-Pro assisted active intervention arm

The device will be placed on patient's heads. Once the device is properly positioned, patient's will undergo a training session/tutorial lasting 2-3 minutes to orient them to the device usage. Personalized family messages recorded by LARs or others will be played at regular intervals up to 5 times per day (between 08:00-18:00) (8 am to 6 pm). Personalized music/brown noise will be played for 15 minutes every 4 hours, which will be modulated according to your reactions/choices. A study team member will assess patient's mental status by asking thinking and memory questions twice a day (AM and PM). The device will perform the same assessments within 30 minutes of those performed by the study team. The device will be removed at 1800/2000 hrs to ensure adequate sleep. Patient's will be in this study arm for up to 7 days of start of study. The device will be removed on day 7 or sooner if patient's do not need ventilator support and standard care will continue as before device usage.

Device: EyeControl-Pro
Based on artificial intelligence (AI)-powered eye-tracking technology, the EyeControl-Pro wearable device and smart platform enable 24/7 customizable communication and monitoring between ventilated patients who cannot speak, their families, and medical teams
Sham Comparator: Sham Control

The device will be placed on patient's heads. Once the device is properly positioned, patient's will undergo a training session/tutorial lasting 2-3 minutes to orient them to the device usage. Patient's will not receive any of the orientation or family messages and no music will be played through the earphones of the device. A study team member will assess patient's mental status by asking thinking and memory questions twice a day (AM and PM). The device will perform the same assessments within 30 minutes of those performed by the study team. The device will be removed at 1800/2000 hrs to ensure adequate sleep. Patient's will be in this study arm for up to 7 days of start of study. The device will be removed on day 7 or sooner if patient's do not need ventilator support and standard care will continue as before device usage.

Other: Control
No intervention

Outcome Measures

Primary Outcome Measures

  1. Proportion of delirium free assessments as assessed by Confusion Assessment Method (CAM) [Upto 7 days or liberation from ventilator whichever is sooner.]

    To evaluate if study subjects randomized to active EyeControl-Pro arm have a higher proportion of delirium free assessments as assessed by CAM (confusion assessment method)-ICU during device usage for up to 7 days when compared with those in the sham EyeControl-Pro arm. CAM-ICU is a validated assessment tool for detection of ICU delirium which provides a binary response delirium present or not.

Secondary Outcome Measures

  1. Delirium severity as measured by Confusion Assessment Method Intensive Care Unit-7(CAM-ICU7) [Upto 7 days or discharge from intensive care unit (ICU) whichever is sooner]

    To evaluate if study subjects in the active EyeControl-Pro arm have lower delirium severity as measured by CAM-ICU7 within first 7 days post randomization or ICU discharge (whichever is sooner) when compared to sham control arm. CAM-ICU 7 is a validated instrument for measurement of delirium severity with scores ranging from 0-7. 0 indicating no delirium to 7 (severe delirium)

  2. Delirium incidence [Upto 7 days or discharge from intensive care unit (ICU) whichever is sooner]

    To evaluate if subjects randomized to the active EyeControl-Pro arm have lower delirium incidence (as measured by CAM-ICU) within first 7 days post randomization or ICU discharge whichever is sooner when compared to sham EyeControl-Pro arm. The CAM-ICU generates a score of 0-4. 0 being no delirium, 4 being severe.

  3. ICU days alive and free of delirium and coma [Upto 7 days or discharge from intensive care unit (ICU) whichever is sooner]

    To evaluate if subjects randomized to the active EyeControl-Pro arm have higher number of days free of coma and delirium within first 7 days post randomization or ICU discharge whichever is sooner when compared to sham EyeControl-Pro arm

Other Outcome Measures

  1. Cognitive scores [30 days post-randomization.]

    To compare cognitive function at 30 days post enrollment using the t-MoCA (telephone-Montreal Cognitive Assessment) or MoCA (if still in-hospital) questionnaire. MoCA is a validated instrument for assessment of cognition with range 0-30 (0-22 for telephonic version) score of over 26 indicates normal.

  2. Depression anxiety scores [30 days post-randomization.]

    To compare depression and anxiety scores at 30 days post enrollment using the HADS (Hospital Anxiety and Depression Scale) questionnaire.HADS ranges from 0-21 with higher scores indicating worse depression or anxiety

  3. CAM ICU concordance [During device usage upto 7 days]

    Agreement between CAM ICU assessment between Eyecontrol and investigator administered CAM-ICU in active intervention arm

  4. Cumulative dose of sedatives [During device usage or upto 7 days whichever is sooner]

    Dose of intravenous sedatives between 2 groups (in mgs/mcgs)

  5. Days free of restraints [Upto 7 days or discharge from intensive care unit]

    Comparison of days free of restraints between 2 groups

  6. Use of rescue medications for delirium and agitation [Upto 7 days or discharge from intensive care unit]

    Use of medications for agitated delirium

Eligibility Criteria

Criteria

Ages Eligible for Study:
50 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

  • Mechanically ventilated patients aged >=50 years

  • RASS score of -3 to +1 and

  • Anticipated to require >=24 hours of mechanical ventilation

Exclusion Criteria:

  • Not expected to survive >=24 hours

  • Have limitations in care (Do Not Resuscitate, or comfort-focused care orders)

  • Receiving paralytic neuromuscular blocking agent (NMBA) infusion or anticipated need for NMBA use

  • Have advanced dementia or cognitive impairment including post-concussive syndrome.

  • Have acute or subacute neurological disorders.

  • Have severe uncorrected psychiatric disorders.

  • Have uncorrected hearing or visual impairment.

  • Have an unstable cervical spine or collar in place limiting movement.

  • Enrolled in a clinical trial which prohibits co-enrollment.

  • Incarcerated

  • Have no identified legally appointed representative (LAR)

  • Are unable to communicate in the predominant local language (English at US site and Hebrew in Israel)

  • Refusal of treating clinical team.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Beth Israel Deaconess Medical Center Boston Massachusetts United States 02215
2 Assuta Ashdod Medical Center Ashdod Israel
3 Rabin Medical Center Petah tikva Israel

Sponsors and Collaborators

  • Beth Israel Deaconess Medical Center
  • BIRD (Israel-United States Binational Industrial Research and Development) Foundation- Funding agency
  • Rabin Medical Center
  • Assuta Medical Center
  • Eyefree Assisting Communication Ltd

Investigators

  • Principal Investigator: Somnath Bose, MD, Beth Israel Deaconess Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Somnath Bose, MD, Assistant Professor of Anesthesia, Harvard Medical School, Beth Israel Deaconess Medical Center
ClinicalTrials.gov Identifier:
NCT06029244
Other Study ID Numbers:
  • 2023P000563
First Posted:
Sep 8, 2023
Last Update Posted:
Sep 14, 2023
Last Verified:
Sep 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:
Delirium
Critical Illness

Study Results

No Results Posted as of Sep 14, 2023